Company news

AngioDynamics, Inc. news in 2024

AngioDynamics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

December 18, 2024

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

December 8, 2024

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

October 22, 2024

AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

October 20, 2024

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

October 2, 2024

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

September 18, 2024

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

September 18, 2024

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

September 2, 2024

AngioDynamics to Participate in Upcoming Investor Conferences

July 28, 2024

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

July 15, 2024

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

July 7, 2024

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

May 20, 2024

AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

May 5, 2024

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

April 3, 2024

AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE

April 3, 2024

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

March 31, 2024

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

March 18, 2024

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

March 5, 2024

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

February 14, 2024

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

January 22, 2024

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

January 4, 2024

Calls in 2024

Decks in 2024